Join to View Full Profile
825 Eastlake Ave ESeattle, WA 98109
Phone+1 206-288-1000
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 2 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Sujata Rao, MD is an oncologist in Seattle, Washington. She is currently licensed to practice medicine in Washington, Pennsylvania, and California.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
UPMC Medical EducationResidency, Internal Medicine, 1984 - 1987
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1984
Certifications & Licensure
CA State Medical License Current
WA State Medical License 1992 - 2026
PA State Medical License 1986 - 1990
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 4 citationsHistological characterization of retinal degeneration in mucopolysaccharidosis type IIIC.Jessica Ludwig, Onkar B Sawant, Jill Wood, Srikanth Singamsetty, Xuefang Pan
Experimental Eye Research. 2023-04-01 - 14 citationsNeuronal Bmal1 regulates retinal angiogenesis and neovascularization in mice.Vijay K Jidigam, Onkar B Sawant, Rebecca D Fuller, Kenya Wilcots, Rupesh Singh
Communications Biology. 2022-08-06 - 4 citationsUnique Sleep and Circadian Rhythm Dysfunction Neuroinflammatory and Immune Profiles in Alzheimer's Disease with Mild Cognitive Impairment.Jagan A. Pillai, James Bena, Lynn M. Bekris, Nancy Foldvary-Schaefer, Catherine Heinzinger
Journal of Alzheimer's Disease. 2021-01-01
Press Mentions
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-Squamous NSCLCSeptember 30th, 2025- Insilico Medicine Begins Clinical Trial for AI-Designed Cancer Drug ISM3412June 26th, 2025
- Insilico Medicine Announces First Patient Dosed in Phase I Clinical Trial of ISM6331, the Novel Inhibitor for the Treatment of Mesothelioma and Other Solid TumorsJanuary 22nd, 2025
- Join now to see all
Grant Support
- Role of melanopsin in outer segment renewalCLEVELAND CLINIC LERNER COM-CWRU2025–2030
- Understanding role of circadian disruption in pathogenesis of MSCLEVELAND CLINIC LERNER COM-CWRU2022–2027
